Skip to main content

Robert E. Beasley, MD, FSCAI, FSIR

Purpose: Patients with chronic limb-threatening ischemia (CLTI) remain at high risk for lower extremity amputations and death. Even with the advent of lower extremity endovascular revascu...
01/17/2022
UltraScore Study Results
First-Time Data Release/LINC 2022
06/07/2022
Dr. Robert Beasley discusses the results of a 12-month study of the clinical use of the UltraScore balloon in a real-world, on-label, clinical application.
Dr. Robert Beasley discusses the results of a 12-month study of the clinical use of the UltraScore balloon in a real-world, on-label, clinical application.
Dr. Robert Beasley discusses the...
06/07/2022
Vascular Disease Management
Original Contribution
04/25/2017
Non-invasive limb hemodynamics may aid in diagnosis of CLI, although the relationship with disease severity and response to endovascular therapy is unclear. This prospective, single-center study enrolled 100 CLI patients who underwent...
Non-invasive limb hemodynamics may aid in diagnosis of CLI, although the relationship with disease severity and response to endovascular therapy is unclear. This prospective, single-center study enrolled 100 CLI patients who underwent...
Non-invasive limb hemodynamics...
04/25/2017
Journal of Invasive Cardiology
Dr Beasley
ISET 2023
01/17/2023
At Tuesday's ISET 2023 sessions, Dr. Robert Beasley presented 3-year results of MIMICS, a prospective, multicenter, observational study that evaluated BioMimics 3D in 507 patients with peripheral arterial disease at 23 investigational sites...
At Tuesday's ISET 2023 sessions, Dr. Robert Beasley presented 3-year results of MIMICS, a prospective, multicenter, observational study that evaluated BioMimics 3D in 507 patients with peripheral arterial disease at 23 investigational sites...
At Tuesday's ISET 2023 sessions,...
01/17/2023
Vascular Disease Management
Original Contribution
05/27/2016
Journal of Invasive Cardiology
Case Study
08/02/2018
The Mount Sinai Medical Center featured the first in-man MicroStent and has thus far completed 5 total cases, all with procedural success and no complications in up to 30-day follow-up.
The Mount Sinai Medical Center featured the first in-man MicroStent and has thus far completed 5 total cases, all with procedural success and no complications in up to 30-day follow-up.
The Mount Sinai Medical Center...
08/02/2018
Cath Lab Digest
FDA Panel
06/28/2019
VDM talks with Robert E. Beasley, MD, FSIR, FSCAI, Director, Vascular/Interventional Radiology Lab and Evanescence Vein Center, Mount Sinai Medical Center, Miami Beach, Florida.
VDM talks with Robert E. Beasley, MD, FSIR, FSCAI, Director, Vascular/Interventional Radiology Lab and Evanescence Vein Center, Mount Sinai Medical Center, Miami Beach, Florida.
VDM talks with Robert E....
06/28/2019
Vascular Disease Management
Clinical Review
04/19/2021
Fibroids are the most common benign tumor in women of reproductive age, and the most common pelvic tumor overall in women. They arise from smooth muscle cells and fibroblasts in the myometrium.
Fibroids are the most common benign tumor in women of reproductive age, and the most common pelvic tumor overall in women. They arise from smooth muscle cells and fibroblasts in the myometrium.
Fibroids are the most common...
04/19/2021
Vascular Disease Management
The STAND Trial: How the MicroStent Attempts to Break Through Barriers in Below-the-Knee CLI
Clinical Update
05/21/2020
To understand the intent behind the STAND (Clinical Evaluation of the MicroSTent PeripherAl Vascular SteNt in Subjects with Arterial Disease Below the Knee) trial, one must comprehend the barriers of clinical success in BTK revascularization.
To understand the intent behind the STAND (Clinical Evaluation of the MicroSTent PeripherAl Vascular SteNt in Subjects with Arterial Disease Below the Knee) trial, one must comprehend the barriers of clinical success in BTK revascularization.
To understand the intent behind...
05/21/2020
Vascular Disease Management